Early Oral Switch for Uncomplicated Gram-negative Bacteraemia

Current management of uncomplicated Gram-negative bacteraemia entails prolong intravenous (IV) antibiotic therapy with limited evidence to guide oral conversion. This trial aim to evaluate the clinical efficacy and economic impact of early switch to oral antibiotics (within 72 hours from index blood culture collection) versus continuing standard of care IV therapy (for at least another 24 hours post-randomisation) for clinically stable / non-critically ill inpatients with uncomplicated Gram-negative bacteraemia.

NCT Number	NCT05199324
Lead Sponsor	Tan Tock Seng Hospital Collaborators: Singapore Clinical Research Institute, Consorzio per Valutazioni Biologiche e Farmacologiche
Conditions	Gram-negative Bacteraemia
Enrollment	720 participants
Start Date	2022-06-03
Primary Completion	2026-05-24 (estimated)
Study Completion	2026-07-23 (estimated)
Updated on ClinicalTrials.gov	2026-08-10